|
MechanismPGC-1α modulators |
|
|
|
Inactive Indication- |
Drug Highest PhaseIND Application |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Endurance Bio, Inc.
0 Patents (Medical) associated with Endurance Bio, Inc.
100 Deals associated with Endurance Bio, Inc.
100 Translational Medicine associated with Endurance Bio, Inc.